卵巢癌组织中lncRNA NORAD的表达水平及其与临床病理特征和预后的相关性

目的:探讨卵巢癌组织中DNA损伤激活的非编码RNA(non-coding RNA activated by DNA damage，NORAD)的表达水平及其与临床病理特征和预后的相关性。方法:选取2019年至2020年于青岛大学附属医院诊治的50例卵巢癌患者和50例正常卵巢患者的组织标本。通过实时荧光定量反转录聚合酶链式反应(qRT-PCR）方法检测以上患者组织中NORAD的相对表达水平，并分析NORAD的表达水平与临床病理特征和预后的关系。使用Kaplan-Meier plotter在线数据库评估NORAD的表达与卵巢癌预后的相关性。结果:NORAD在卵巢癌组织中呈高表达，其表达与FIGO分期、组织类型、腹水以及淋巴结转移相关(P＜0.05)。NORAD高表达的卵巢癌患者5年无进展生存期(progression-free survival，PFS)显著低于低表达组。NORAD在卵巢癌组织中的表达水平在FIGO分期、病理分级、TP53状态以及化疗方面对患者的预后具有评估价值。结论:卵巢癌组织中NORAD表达水平明显升高,且其水平与卵巢癌临床病理特征及预后相关。     

CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma

We investigated the expression of CD44 and MMP-9 in primary oral squamous cell carcinoma (OSCC) and evaluated their association with each other and clinicopathological factors as well as their prognostic value during long term follow up. Histological samples from 138 OSCC patients were immunohistochemically stained for the expression of CD44 and MMP-9. The staining results were compared with conventional prognostic factors and their impacts to patients' prognosis were also studied with survival analyses. Irregular staining of CD44 in tumour cells was associated with poor tumour differentiation (p=0.003), higher clinical stage (III-IV) (p=0.049), and the presence of T3-4 tumour stage (p=0.03). Strong stromal MMP-9 staining intensity was correlated with poor tumour differentiation (p=0.03). In univariate survival analysis irregular staining of CD44 in tumour cells was related to poor disease free and overall survival (p=0.001 and p<0.001, respectively). In multivariate analysis CD44 staining was a significant independent predictor for overall (p=0.03) and disease free survival (p=0.003). MMP-9 expression showed no statistical significance in survival analyses. Strong stromal staining intensity of MMP-9 correlated with irregular staining of CD44 in tumour cells, but had no prognostic significance in the present cohort. However, irregular staining of CD44 predicted more advanced disease and shortened survival of the patients.     

Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer

Cervical cancer remains one of the most common malignancies in women. Previous study proved MMP-9 might be prognostic marker for multiple human malignancies. The present study was to investigate the protein expression of MMP-9 in cervical cancer and its association with clinicopathological characteristics as well as prognosis of patients. Cervical cancer specimens from 225 cases who had not received chemotherapy or radiotherapy prior to surgery were collected. Immunochemistry assays were utilized to investigate MMP-9 protein expression. Results showed that MMP-9 expression was increased in cervical cancer and associated with stromal invasion, FIGO stage, lymph node metastasis, and vascular invasion. Kaplan?CMeier analysis showed that patients with cervical cancer of positive MMP-9 staining tend to have worse overall survival. In multivariate analysis stratified for known prognostic variables, MMP-9 was proved to be an independent prognostic factor. The present study confirmed that MMP-9 expression in cervical cancer was an independent prognostic factor of patients, which might be a potential diagnostic and even therapeutic target of cervical cancer.     

基质金属蛋白酶-9在胃癌中的表达及其预后价值

目的 探讨基质金属蛋白酶-9（MMP-9）在胃癌组织中的表达情况,分析其表达     

Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer

Matrix metalloproteinase-9 is a member of the Matrix metalloproteinases (MMP) family, which is overexpressed in some solid tumor and thought to enhance the tumor invasion and metastasis ability. Our study is to investigate the association of MMP-9 expression with disease-free survival and overall survival of patients with gastric cancer. Clinical gastric cancer specimens and adjacent normal tissues from 286 patients who had not received neoadjuvant chemotherapy were investigated by immunohistochemistry assay. Staining evaluation results were analyzed statistically in relation to various clinicopathological characters, disease-free survival and overall survival. High level of MMP-9 expression was detected in gastric cancer, significantly more than in adjacent normal epithelial cells. In gastric cancer, MMP-9 was significantly positively correlated with depth of invasion, lymph node metastasis and distant metastasis. However, no correlations between MMP-9 expression and patients' age, sex, tumor location or differentiation status were detected. The disease-free survival and overall survival were significantly shorter for patients with MMP-9 positive than those with MMP-9 negative tumors. Multivariate analysis identified MMP-9 was an independent prognostic factor for both disease-free survival and overall survival. Our findings provided convincing evidence for MMP-9 as an important role in human gastric cancer recurrence and prognosis. It might also serve as a novel target for both prognostic prediction and therapeutics.     

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

BACKGROUND: Malignant ascites is a manifestation of end stage events in a variety of cancers and associated with a poor prognosis. We evaluated the pattern of cancers causing malignant ascites and factors affecting survival. PATIENTS AND METHODS: Patients coded with the International Classification of Diseases-9 coding system for malignant ascites over a 2-year period were reviewed. The clinicopathological data and patients' survival were compared among cancer groups. RESULTS: There were 209 patients (140 females and 69 males), median age being 67 (30-98) years. The commonest cancer was ovarian followed by gastrointestinal (GI) cancers. Fifty-eight per cent of the patients had symptoms related to the ascites. Liver metastases were significantly commoner in the GI cancers (P = 0.0001). Fifty-four per cent of our patients presented with ascites at the initial diagnosis of their cancer. Paracentesis was given to 112, diuretics to 70 and chemotherapy to 103 patients. The median survival following diagnosis of ascites was 5.7 months. Ovarian cancer favoured longer survival while low serum albumin, low serum protein and liver metastases adversely affected survival. The independent prognostic factors for survival were cancer type, liver metastases and serum albumin. CONCLUSION: The identified independent prognostic factors should be used to select patients for multimodality therapy for adequate palliation.     

Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.

PURPOSE: To analyse the negative versus positive immunoexpression of E-cadherin in patients with primary ovarian carcinomas, and determine its significance in relation to clinicopathological features, overall and recurrence-free survival (RFS). PATIENTS AND METHODS: The protein expression of E-cadherin was immunohistochemically evaluated in formalin-fixed, paraffin-embedded samples in 104 patients with primary ovarian carcinomas. The clinicopathological factors studied were age, FIGO staging, histological type, tumour differentiation, the appearance of the ovarian capsule, peritoneal implants and residual tumour after cytoreductive surgery. Overall survival and RFS were evaluated using the Kaplan-Meier method, and multivariate analysis was completed using the Cox regression model. RESULTS: Of the 104 carcinomas, negative E-cadherin immunoexpression was observed in seven (7%) cases, and positive immunoexpression in 97 (93%). E-cadherin categorised into negative versus positive expression did not associate with any of the established clinicopathological parameters. However, negative E-cadherin expression significantly predicted a poorer overall survival when compared with positive expression (P=0.006). In the multivariate analyses, negative E-cadherin and the presence of residual tumour after cytoreductive surgery were independent prognostic factors for survival (P=0.014 and P=0.034, respectively). CONCLUSIONS: The presence of residual tumour after primary cytoreductive surgery and negative E-cadherin expression seem to be useful markers in patients with ovarian carcinomas likely to have an unfavourable clinical outcome. The assessment of E-cadherin immunoreactivity may be a useful prognostic indicator in ovarian cancer, complementary to established prognostic factors.     

Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis

Matrix metalloproteinases (MMPs) have been shown to have a significant role in determining cancer cell behaviour. The present study was undertaken to analyze the expression and prognostic value of MMP-7 and MMP-9 in non-small cell lung cancer (NSCLC). The relationship of MMP-7 with beta-catenin was also evaluated. The study consists of 212 patients with resected NSCLC. Tumour samples were stained immunohistochemically, and the expression of MMP-7 and MMP-9 was evaluated in both tumour cells and peritumoural stromal tissue. The results were compared to clinicopathological factors of the patients. A high staining of MMP-7 and MMP-9 in tumour cells was noted in 62 (30%) and 113 (57%) cases, respectively. Expression of MMP-7 was noted more often in adenocarcinomas than in other histological types (p=0.022). High cancer cell associated MMP-7 was related to lower T-factor (p=0.037), better tumour differentiation (p=0.005) and normal beta-catenin expression in tumour cells (p=0.001). A high MMP-9 expression in tumour cells was related to poor tumour differentiation (p=0.016). The stromal signal for MMP-9 was observed in 58 (32%) cases and was linked with higher tumour grade (p=0.031). In survival analyses the significant predictors of survival were histological type of tumour and tumour stage (p=0.0009 and 0.0012, respectively). MMP-7 or MMP-9 signals were not related to patient's outcome. The results show that high MMP-9 expression indicates aggressive, and high MMP-7 less aggressive tumour behaviour in NSCLC. However, MMP-7 and MMP-9 expressions had no prognostic value in NSCLC.     

The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.

PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful. In the present study, we evaluated the significance of the M:E ratio as a predictor for prognosis for patients with TCC in the upper urinary tract (TCC-UUT). EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy. The expression of angiogenesis, angiogenic and metastasis-related factors, and clinicopathological characteristics were evaluated for their correlation with metastasis, recurrence, and disease prognosis. RESULTS: We found that tumor grade and pathological stage were important predictors for metastasis and survival in these patients. The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD. Increased MVD, elevated expression levels of MMP-9 and MMP-2, and a higher M:E ratio were associated with poor prognosis. Moreover, lower expression levels of E-cadherin were associated with fewer recurrences in the urinary bladder. Multivariate analysis indicated that the M:E ratio and E-cadherin expression were independent prognostic factors for disease progression and intravesical recurrence, respectively. CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.     

MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not

The prognostic significance of single-nucleotide polymorphisms (SNPs) and tumour protein levels of MMP-2 and MMP-9 was evaluated in 215 colorectal cancer patients. Single-nucleotide polymorphism MMP-2(-1306T) and high MMP-2 levels were significantly associated with worse survival. Extreme tumour MMP-9 levels were associated with poor prognosis but SNP MMP-9(-1562C>T) was not. Tumour MMP levels were not determined by their SNP genotypes.     

Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis

Background: Matrix metalloproteinase-9 (MMP-9) is associated with disruption of basement membranesof blood vessels and promotion of metastasis through the lymphatics. However, its prognostic value for survivalin patients with gastric cancer remains controversial. Method: We therefore conducted a meta-analysis of thepublished literature in order to clarify the impact of MMP-9. Clinical studies were selected for further analysisif they provided an independent assessment of MMP-9 in gastric cancer and reported analysis of survival dataaccording to MMP-9 expression. Results: A total of 11 studies, covering 1700 patients, were included for metaanalysis.A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combinedHR suggested that a positive MMP-9 expression had an impact on overall survival: 1.25 (95% confidence interval1.11-1.40) in all eligible studies; 1.13 (1.06-1.20) in 8 studies detecting MMP-9 by immunohistochemistry; 1.36(1.12-1.65) in 7 studies from Asia. Only one study for DFS showed a significant impact on disease free survival(HR 1.73, 95%CI 1.27-2.34). Conclusions: Our findings suggested that MMP-9 protein expression might be afactor for a poor prognosis in patients with gastric cancer. However, the association was rather weak, so that moreprospective studies should further explore the prognostic impact of MMP-9 mRNA and correlations betweenMMP-9 and clinicopathological characteristics.     

Expression and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases as a prognostic factor in advanced colorectal carcinomas

To clarify the usefulness of matrix metallo-proteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) as prognostic factors in advanced colorectal carcinoma, the immunohistochemical expressions of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 were examined. Specimens were selected from 67 consecutive patients undergoing surgery for advanced colorectal carcinoma. The patterns of expression were compared with the prognoses of the patients. The patients with TIMP-2 expression in stroma adjacent to the tumor mass had better prognoses than those of the patients who had no TIMP-2 expression in normal stroma adjacent to the tumor (p<0.05), which probably acted as a block of cancer cell invasion. However, the expression of MMP-2, presumably acting as an antagonist to TIMP-2 was not related to the prognosis, and the MMP-1, MMP-2, MMP-3, MMP-9 and TIMP-1 expressions were not related to any clinicopathological factors examined.     

基质金属蛋白酶及其组织抑制物在卵巢肿瘤中的表达

背景与目的：有研究表明,基质金属蛋白酶（metalloproteinases,MMPs）与肿瘤的发生发展,尤其是肿瘤细胞的侵袭和转移密切相关。本研究探讨基质金属蛋白酶MMP－2、MMP－9及其组织抑制物（tissue inbibitor of metalloproteinases-2,TIMP-2）与卵巢癌侵袭及卵巢癌生物学行为的关系。方法：采用免疫组化S－P法对128例卵巢肿瘤组织MMP－2、MMP－9及TIMP－2蛋白表达进行检测,并用Χ^2检验进行统计学分析。结果：免疫组化结果表明,MMP－2、MMP－9及TIMP－2在卵巢癌组织中阳性表达率明显高于卵巢囊腺瘤（P＜0．01）。MMP－2及MMP－9在卵巢癌临床分期Ⅲ-Ⅳ期病例中的阳性表达率明显高于I－Ⅱ期者,病理学分级3级病例中的表达率明显高于1－2级者（P＜0．01）,有淋巴结转移病例中的表达率明显高于无淋巴结转移者（P＜0．01）。而TIMP－2的阳性表达与MMP－2及MMP－9相反。结论：MMP－2、MMP－9及TIMP－2的表达与卵巢癌的临床分期、病理分级及淋巴结转移有关,MMP－2及MMP－9蛋白的高表达可作为判断卵巢部具有转移倾向的临床参考指标。     

LncRNA ZEB2-AS1在卵巢癌组织中的表达水平及临床病理特征与预后的关系

目的:探讨长链非编码核糖核酸（LncRNA）锌指E盒结合同源盒蛋白2-AS1（LncRNA ZEB2-AS1）在卵巢癌组织中的表达水平，并分析其与患者临床病理特征及预后的关系。方法:收集2015年3月至2016年3月本院收治的卵巢癌患者90例为卵巢癌组，同时选取同期于本院体检的健康志愿者52例为对照组。实时荧光定量聚合酶链反应(qRT-PCR)检测LncRNA ZEB2-AS1表达水平。收集患者临床病理资料，根据LncRNA ZEB2-AS1表达水平检测结果将其分为高表达组（52例）与低表达组（38例），分析其与患者临床病理特征关系。对卵巢癌患者随访3年，采用Kaplan-Meier法分析LncRNA ZEB2-AS1表达与患者预后关系。采用Cox比例风险模型分析影响卵巢癌患者预后的相关因素。结果:卵巢癌患者血清LncRNA ZEB2-AS1表达水平显著高于对照组（P<0.05）；LncRNA ZEB2-AS1表达水平与卵巢癌患者是否发生淋巴结转移、FIGO分期、分化程度及CA125水平明显相关（P<0.05）；Kaplan-Meier法分析显示LncRNA ZEB2-AS1高表达组患者3年无疾病进展生存率与总生存率分别为25.00%、46.88%，LncRNA ZEB2-AS1低表达组患者PFS与OS均显著低于低表达组（P<0.05）；Cox多因素分析显示淋巴结转移、FIGO分期、LncRNA ZEB2-AS1表达均是影响卵巢癌患者预后的独立危险因素（P<0.05）。结论:卵巢癌患者血清LncRNA ZEB2-AS1表达水平明显升高，且与患者临床病理特征及预后密切相关，可能作为卵巢癌早期诊断的标记物及治疗靶点。     

Prognostic Value of MMP-9 in Ovarian Cancer: A Meta-analysis

Objective: Matrix metalloproteinase-9(MMP-9) plays an important role in tumor cell invasion. Althoughit has been studied frequently in ovarian cancer, its prognostic impact is still equivocal. The aim of this studywas to more precisely estimate its prognostic significance. Method:We searched Pubmed, Embase, OVID,Sciencedirect and CBM databases to identify eligible studies. Hazard ratios (HRs) or odds ratios (ORs) with 95%confidence intervals (95% CIs) were pooled across studies using fixed-effects or random-effects models. We alsoperformed subgroup analysis. Results: 30 studies (n=2552 patients) focusing on prognosis or expression of MM-9were included. Increased expression of MMP-9 was associated with poor prognosis in ovarian cancer patients(HR=1.68, 95%CI 1.09-2.59, p=0.02). Besides, MMP-9 expression in ovarian cancer was significantly higher thannon-malignant tumors (OR=11.46, 95%CI 8.47-15.50, P<0.00001). Moreover, increased expression of MMP-9was significantly associated with FIGO stage (OR=4.85, 95%CI 2.60-9.04, P<0.00001), grade of differentiation(OR=3.34, 95%CI 2.46-4.54, P<0.00001), lymph node metastasis (OR=5.75, 95%CI 3.71-8.92, P<0.00001) andthere was no association with histological type of ovarian cancer. Conclusions: Increased expression of MMP-9 was associated with poor prognosis in ovarian cancer patients. Down-regulation of MMP-9 is an attractivetherapeutic approach which might improve outcome of ovarian cancer.     

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.

BACKGROUND: Matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) are two proteins involved in angiogenesis. In the present study we investigated the association of pretreatment MMP-9 and VEGF serum levels with clinicopathological parameters and outcome in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: From February 1998 to October 1999, pretreatment serum levels of MMP-9 and VEGF were analysed in 118 patients with enzyme-linked immunoassays. At diagnosis 50 patients (42%) were staged as early disease (I/II), 27 patients (23%) as locally advanced (IIIA/IIIB), and 41 patients (35%) had metastatic disease (IV). In 72 of the 118 patients tumours were resected and 46 patients received combination chemotherapy with gemcitabine and vinorelbine. RESULTS: The median survival of all 118 patients was 602 days. The 72 patients who had undergone surgery had a median survival of 972 days and the 46 patients who were treated with chemotherapy had a median survival of 298 days (P <0.001). Resected patients with stage I/II disease and an MMP-9 serum level 相似文献   

CXCL12及受体CXCR4在卵巢上皮性癌中的表达及其临床意义

目的:探讨趋化因子CXCL12及其受体CXCR4在卵巢上皮性癌组织中的表达及与临床病理特征和预后的关系。方法:采用免疫组织化学SP法检测6例正常卵巢表面上皮、44例卵巢上皮性癌原发灶和30例相应大网膜转移灶组织中的CXCL12和CXCR4蛋白表达。结果:正常卵巢表面上皮无CXCL12和CXCR4蛋白表达;卵巢上皮性癌原发灶的CXCL12和CXCR4表达阳性率分别为91%和59%。CXCL12表达强度与术中腹水量有显著相关性(P=0.014)。难治复发组的CXCR4阳性率(81%)显著高于无复发组(28%,P<0.001)。单因素分析显示:CXCR4阳性表达的患者中位数肿瘤无进展生存时间和总生存时间(15个月、27个月)明显短于CXCR4阴性表达者(>21个月、>32个月,分别为P<0.001和P=0.017)。多因素分析显示:CXCR4表达和残余灶大小是影响卵巢上皮性癌患者的肿瘤无进展生存时间和总生存时间的独立预后因素。结论:CXCR4在卵巢上皮性癌中的表达阳性率较高,是影响其预后的独立指标之一。     

卵巢癌血清相关miRNAs的筛选及其临床意义

背景与目的：卵巢癌预后较差,发现时通常是晚期,需找寻与卵巢癌发生、发展相关的诊治方法。该研究检测miRNA在上皮性卵巢癌患者术前外周血清及良性卵巢肿瘤患者外周血清中表达情况的差异,筛选差异有统计学意义的miRNA并分析其与上皮性卵巢癌患者临床病理特征、预后等的关系。方法：定制研究相关的48种miRNA表达谱芯片,通过TaqMan低密度微阵列芯片,筛选出有统计学意义的miRNA。采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,RTFQ-PCR)法验证筛选的miRNA在卵巢良、恶性肿瘤患者血清中的表达情况,选择具有统计学意义的miRNA行大样本验证并分析其与肿瘤分期、组织病理及预后等的关系。结果：通过TaqMan低密度微阵列芯片筛选和RTFQ-PCR验证,发现miR-125b在上皮性卵巢癌患者血清中的表达高于良性肿瘤患者(P=0.039),miR-125b在早期患者中的表达量高于晚期患者(P=0.003),术后无残余肿瘤患者表达量高于术后有残余肿瘤患者(P=0.013)。血清miR-125b高表达有利于卵巢癌患者无进展生存期(progression-free survival,PFS)延长(P=0.003),但对总生存期(overall survival,OS)无明显影响(P=0.069)。结论：miR-125b在上皮性卵巢癌的发生、发展中起着关键作用,与患者预后相关,是预测卵巢癌复发的潜在基因,但在肿瘤不同期别的表达情况发生变化,在早期作用比较明显,在晚期或肿瘤残余较多的患者表达较不明显,其作用机制有待进一步研究。     

血浆D-二聚体水平与卵巢癌患者临床特征及化疗预后的关系研究

目的 探讨血浆D-二聚体(D-D)水平与卵巢癌患者临床特征及化疗预后的关系.方法 收集106例卵巢癌患者的临床资料,根据患者血浆D-D水平,将患者分为正常组(≤0.3 mg/L)及升高组(>0.3 mg/L).比较两组患者的临床特征、生存率,分析影响卵巢癌患者化疗预后的危险因素.结果 两组患者FIGO病理分期比较,差异有统计学意义(P﹤0.05);两组患者年龄、组织分化程度、淋巴结转移情况、病理类型及恶性腹腔积液情况比较,差异均无统计学意义(P﹥0.05).升高组患者中位OS及PFS分别为29.7个月(95%CI:27.6~31.8)、9.1个月(95%CI:7.7~10.4);正常组患者中位OS及PFS分别为38.6个月(95%CI:35.8~41.4)、16.1个月(95%CI:13.0~19.2);升高组患者中位OS及PFS明显低于正常组,差异均有统计学意义(Z=13.527、18.461;P﹤0.01).单因素分析结果显示年龄、FIGO病理分期、淋巴结转移、恶性腹腔积液、新辅助化疗、CA125水平、血浆纤维蛋白原、血小板、血浆D-D水平是卵巢癌患者化疗预后的影响因素(P﹤0.01),进一步经Cox回归模型分析结果显示,FIGO病理分期Ⅲ~Ⅳ期、有淋巴结转移、有恶性腹腔积液、无新辅助化疗、血浆D-D水平﹥0.3 mg/L是影响卵巢癌患者化疗生存预后的独立危险因素(P﹤0.01).结论 血浆D-D水平升高是影响卵巢癌患者化疗生存预后的独立危险因素,可作为评估卵巢癌患者化疗生存预后的指标.